Looking back, the end of the 2nd cohort dosing was announced on the 17th Dec 2021, with a readout of how that cohort went in the beginning of February 2022.
So maybe a readout of the 3rd cohort soonish.
3 of the 4 patients showed signs of localised stabilising disease in the second cohort. Fingers crossed the higher dose given to the 3rd cohort builds on that result.
The patients in this trial have already had the SOC fail for them. So life expectancy is measured in months. There is no real cure for GBM.
Still a high risk investment, but a positive readout from the 3rd cohort would put us one step closer to that fast track drug approval pathway. Meaning an expanded phase 2b trial may be all that is needed to get this drug to market. if it works.
Some CarT early to market drugs were given approvals after phase 1 trials of only 75 patients. This is pie in the sky stuff, but there is precedence for disease with no effective treatment. GBM ticks that box. The CHM team were involved in getting some of those other CarT drugs to market. Aline of credit is already in place to progress the drug development, so no CR will be required for a considerable time.
Exciting times ahead with huge potential from this market cap.
CHM Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)